These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 30539709)
1. [ Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709 [TBL] [Abstract][Full Text] [Related]
2. Role of positron emission tomography in thyroid and neuroendocrine tumors. Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122 [TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer. Giovacchini G; Giovannini E; Riondato M; Ciarmiello A Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291 [TBL] [Abstract][Full Text] [Related]
4. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146 [TBL] [Abstract][Full Text] [Related]
5. NEN - the role of somatostatin receptor scintigraphy in clinical setting. Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789 [TBL] [Abstract][Full Text] [Related]
6. Added value of [ Yoo J; Kim SH; Jeon SK; Bae JS; Han JK Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974 [TBL] [Abstract][Full Text] [Related]
7. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP). Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589 [TBL] [Abstract][Full Text] [Related]
8. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465 [TBL] [Abstract][Full Text] [Related]
9. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China. Liu M; Cheng Y; Bai C; Zhao H; Jia R; Chen J; Zhu W; Huo L Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2002-2011. PubMed ID: 38337073 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm. Johnbeck CB; Mortensen J PET Clin; 2021 Apr; 16(2):191-203. PubMed ID: 33648664 [TBL] [Abstract][Full Text] [Related]
11. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance and clinical impact of Hou G; Cheng X; Yang Y; Zhao D; Wang G; Zhao H; Zheng R; Wang X; Chen X; Chi Y; Zhang J Theranostics; 2024; 14(8):3213-3220. PubMed ID: 38855183 [No Abstract] [Full Text] [Related]
13. Comparison of [ Chen D; Yang S; Chen J; Li T; Liu Y; Zhao X; Zhang T; Xu M; Wang H; Zhao K; Su X Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2420-2431. PubMed ID: 36971805 [TBL] [Abstract][Full Text] [Related]
14. State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms. Ambrosini V; Fortunati E; Fanti S; Ursprung S; Asmundo L; O'Shea A; Kako B; Lee S; Furtado FS; Blake M; Goiffon RJ; Najmi Z; Hesami M; Murakami T; Domachevsky L; Catalano OA J Comput Assist Tomogr; 2024 Jul-Aug 01; 48(4):510-520. PubMed ID: 38518197 [TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911 [TBL] [Abstract][Full Text] [Related]
16. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220 [TBL] [Abstract][Full Text] [Related]
17. Guideline for PET/CT imaging of neuroendocrine neoplasms with Bozkurt MF; Virgolini I; Balogova S; Beheshti M; Rubello D; Decristoforo C; Ambrosini V; Kjaer A; Delgado-Bolton R; Kunikowska J; Oyen WJG; Chiti A; Giammarile F; Sundin A; Fanti S Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1588-1601. PubMed ID: 28547177 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [ Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results. Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]